Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

data-sets have been transferred and the authorities have confirmed the receipt and navigability of the information. Both the rolling NDA and the electronic format could greatly facilitate the review process.

The first modules of the NDA package are ready and will be filed before year-end 2007. The remaining modules are expected to be transferred and filing is forecast to be completed by the end of February 2008.

Dr Khalid Islam, President and CEO of Arpida Ltd., commented: "We are pleased with the progress made across the several different programmes.

Firstly, initiation of patient enrolment in the Phase II trial with intravenous iclaprim in HAP/VAP/HCAP provides a good basis for the completion of the trial within the planned timelines. HAP/VAP/HCAP is a serious, life-threatening condition with a high medical need. We believe that iclaprim could have a high potential in this indication based on its potent and bactericidal action on MRSA and its good distribution in those lung compartments where the key respiratory pathogens reside."

Dr Islam added: "Moreover, we are very pleased with the results of the ascending dose trial with oral iclaprim, which show a good tolerability at high doses. We are now working to complete the Phase I programme while at the same time discussing with the regulatory authorities regarding the potential next steps in the development path of oral iclaprim.

Work on the NDA for intravenous iclaprim in cSSSI is progressing well. We expect to file the first modules of the package before year-end and complete the filing by the end of February 2008. After finalising the NDA filing, our next steps will focus on the preparation of the commercial launch of iclaprim."

Conference Call

Arpida will host a conference call to discuss these recent developments, today, 11 December 2007, at 3 pm CET. The dial-in numbers are:

+41-(0)91-610-56-00 (Europe)

+44-(0)207-107-06-11 (UK)

+1-(1)866-29
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 -- A novel combination of microscopy ... of Energy,s Oak Ridge National Laboratory an unprecedented look ... unusual physical and electrochemical properties. , The research ... affects the surface of a perovskite manganite, a complex ... new avenue to understand surface behavior could benefit researchers ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... Yung-Eun Sung has announced that they have developed ... which can be applied as high performance electrodes ... is both a group leader at the Center ... (IBS) and a professor at the Seoul National ... regards to the development of relative simplicity, scalablity, ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... and scale of EDS services allow Bristol-Myers Squibb to ... focus on core biopharmaceutical business, ... million information technology (IT) services contract that,calls for EDS to ... scope and scale will allow the company to,improve productivity so ...
... SpectraScience, Inc. (OTC,Bulletin Board: SCIE) announced today that ... of Finance and Chief Financial Officer., Jim Hitchin ... many years of,experience in public medical device, manufacturing and ... 25 years ago. With a graduate,degree in accounting, he ...
... Dec. 10 iCAD, Inc. (Nasdaq:,ICAD), an industry-leading ... identification of cancer, today announced that two,U.S. Patents, ... granted,to the Company by the United States Patent ... our on-going commitment to broadening,and protecting our intellectual ...
Cached Biology Technology:EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 2EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services 3Jim Dorst Joins SpectraScience as CFO 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 3
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... 45% on average over a 35 year period in ... the impact of humans on declining animal numbers. This ... as insects, spiders, crustaceans, slugs and worms bring to ... crops, decomposition for nutrient cycling, water filtration and human ... and led by UCL, Stanford and UCSB, focused on ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... working in College of Life Science, Zhejiang University, has ... CpG island has a parental differentially methylated region (DMR). ... imprinting exists in lower vertebrates and genomic imprinting should ... mammals. The study is reported in volume 54 (Issue ...
... A team of University of Oregon biologists, using fruit ... specific cells, opening a new window on how gene ... While DNA (deoxyribonucleic acid) provides an identical genetic blueprint ... that turn protein molecules on and off in different ...
... is the latest American Chemical Society (ACS) Weekly PressPac ... from ACS, 34 peer-reviewed journals and Chemical & Engineering ... Society as the source for this information. ... melamine-adulterated food , Journal of Agricultural and Food ...
Cached Biology News:The evolutionary foundation of genomic imprinting in lower vertebrates 2New tool isolates RNA within specific cells 2American Chemical Society's Weekly PressPac -- May 13, 2009 2American Chemical Society's Weekly PressPac -- May 13, 2009 3American Chemical Society's Weekly PressPac -- May 13, 2009 4American Chemical Society's Weekly PressPac -- May 13, 2009 5American Chemical Society's Weekly PressPac -- May 13, 2009 6American Chemical Society's Weekly PressPac -- May 13, 2009 7American Chemical Society's Weekly PressPac -- May 13, 2009 8American Chemical Society's Weekly PressPac -- May 13, 2009 9American Chemical Society's Weekly PressPac -- May 13, 2009 10
hnRNP U (H-94)...
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
... causing shortages in your laboratory or fellow ... unwanted distractions, problems and delays. ... hard work and endeavour! Bring us your ... market it internationally. We work under ISO ...
... from vaccinia virus is a type I ... negative superhelical turns (also called right- and ... product of the reaction is a covalently ... negative superhelical turns. DNA Topoisomerase I does ...
Biology Products: